摘要

Objectives: - Evaluate the effectiveness of non-ablative fractional laser in the treatment of inflammatory acne. - Analyze the impact of laser treatment on life quality of patients participating through the application of the Dermatology Quality of Life Index (DLQI). - Quantify the improvement in the severity of acne before and after treatment. - Evaluate satisfaction, tolerability and adverse effects of the fractional laser with a questionnaire applied to patients. Introduction: Acne is a chronic inflammatory disease of the pilosebaceous unit whose pathogenesis is multifactorial and it presents a pattern of relapse difficult therapeutic management, which has an important psychosocial impact associated. The use of lasers and technologies in the treatment of acne has increased recently due to their safety and effectiveness. This study aims to evaluate the effectiveness of using a non-ablative Nd:YAP 1340 fractional laser in the treatment of inflammatory acne. Materials / method: 8 patients with facial inflammatory acne underwent 4 Nd:YAP 1340nm laser sessions with an interval of 30 days between them. Data were collected by evaluating pre and post-procedure photographs, pre and post-procedure active acne severity index scale and Dermatology Life Quality Index (DLQI) questionnaire before and after treatment, in addition to the satisfaction and tolerability answered by patients at the end of treatment. Results: All of the 8 participants who completed the study showed a positive outcome after applying laser therapy in relation to the severity of their acne, with no worsening in any of the cases. Regarding the patient's subjective assessment, all of them showed a drop in their DLQI score, from 22.62 points (pre-treatment average) to 4.37 (post-treatment average). No side effects were observed during the treatment. Conclusion: The treatment with non-ablative fractional Nd:YAP 1340nm laser proved to be effective and safe in the treatment of inflammatory acne, being a promising tool in this condition. The method can be considered as an adjuvant to conventional therapy and should be considered as an alternative in patients who are resistant to systemic medications and in those with intolerance to systemic or topical medication. Further studies with more patients and longer follow-up time are necessary in order to consolidate the author's conclusion.